Brief: Candel Therapeutics Inc Reports Q2 Net Loss Per Share Of $0.14

Candel Therapeutics

05/08/2022 13:19

Aug 5 (Reuters) - Candel Therapeutics Inc  CADL.O :
    * CANDEL THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS AND RECENT CORPORATE HIGHLIGHTS
    * CANDEL THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF
JUNE
30, 2022 WERE $86.8 MILLION COMPARED TO $82.6 MILLION AS OF
DECEMBER 31, 2021
    * CANDEL THERAPEUTICS INC - EXPECTS THAT ITS EXISTING CASH
AND
CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO
Q1 OF 2024
    * CANDEL THERAPEUTICS INC - QTRLY NET LOSS PER SHARE
ATTRIBUTABLE
TO COMMON STOCKHOLDERS, BASIC AND DILUTED $0.14

Source text for Eikon:  ID:nGNX557YCV 
Further company coverage:  CADL.O 

 ((Reuters.Briefs@thomsonreuters.com;;))